Antipsychotic Dose Reduction Increases Mental Health-Related and All-Cause Hospitalizations

The study was initiated and sponsored by TEVA Pharmaceuticals, which markets deutetrabenazine (Austedo), one of two approved treatments for tardive dyskinesia.

1 Like